<DOC>
	<DOCNO>NCT00828737</DOCNO>
	<brief_summary>Patients moderate severe renal impairment schedule magnetic resonance imaging ( MRI ) scan injection contrast agent , Gadovist , ask participate . The administration contrast agent contain gadolinium Gadovist might increase potential risk develop rare condition call nephrogenic systemic fibrosis ( NSF ) patient renal impairment . This study assess potential risk develop NSF patient renal impairment administration Gadovist . Patients enrol study receive Gadovist enhance MRI scan prescribe refer doctor . After MRI scan patient include two year follow-up period ass sign symptom suggestive NSF appear .</brief_summary>
	<brief_title>Safety Gadovist Renally Impaired Patients</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Patients moderate ( eGFR 30 59 ml/min/173m2 ) severe ( eGFR &lt; 30 ml/min/1.73m2 ) renal impairment , schedule undergo Gadovistenhanced MRI GBCAenhanced MRI ( administration GBCA CE image procedure ) Gadovist within 12 month prior administration Gadovist History NSF ( Nephrogenic Fibrosing Dermopathy ) Age outside indicate age range mention national labelling .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>